SOPHiA GENETICS SA is a cloud-native software technology company in the healthcare sector that provides a decentralized analytics platform for data-driven medicine. Founded in 2011, the company offers SOPHiA DDM, a platform that standardizes, computes, and analyzes complex multimodal digital health data, including genomic, radiomic, clinical, and biological data. The company’s applications support precision medicine across oncology, rare diseases, infectious diseases, cardiology, neurology, and metabolism. Key products include SOPHiA CarePath, a multimodal module powered by artificial intelligence and machine learning, and the Digital Twins tool, which creates virtual representations of patients to simulate treatment outcomes. SOPHiA GENETICS serves healthcare providers, clinical and life sciences research laboratories, and biopharmaceutical companies globally. The company commercializes its solutions as Research Use Only (RUO) products in the United States and as CE-IVD products in the European Economic Area, the United Kingdom, Switzerland, and Israel. Its decentralized model allows customers to retain custody of their samples and data while sharing insights through a global network.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Health Information Services Homepage sophiagenetics.com
Sector Healthcare IR page ir.sophiagenetics.com
Tags
precision medicine, genomics, radiomics, oncology, rare diseases, multimodal data analytics, cloud-native software, artificial intelligence, machine learning, clinical diagnostics, SOPHiA DDM, SOPHiA CarePath, Digital Twins, SOPHiA DDM Dx Hereditary Cancer Solution, SOPHiA DDM Dx RNAtarget Oncology Solution, SOPHiA DDM Dx Homologous Recombination Deficiency Solution, SOPHiA DDM Dx Myeloid Solution, SOPHiA DDM Dx Solid Tumor Solution, Alamut
Press page sophiagenetics.com/press-releases

Metrics

Valuation  
Market cap $ 522.09M
Market cap (USD) $ 522.09M
P/E -6.66
PEG —
P/BV 6.28
P/S 6.06
P/OCF -13.14
P/FCF -12.67
Dividend yield —
Turnover / mcap —
Returns  
ROE -110.0%
ROI -83.3%
ROIC -56.1%
Profit margin -102.2%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 57.7%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 5
Quality score -35.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 77.271M 65.173M 62.371M 47.56M 40.45M 28.4M
Net profit -78.999M -62.493M -78.981M -87.449M -73.675M -39.339M
Free cash flow -36.467M -43.066M -50.069M -74.19M -60.622M -32.18M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 4.67 3.1 4.71 2.06 14.1 —
Price performance 12m 0.51 -0.34 1.29 -0.85 — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Income detail
Research and development expense (USD) 15M 18.6M 26.6M 35.4M 37M 34.4M 34.2M
↳ 5y CAGR +18.0% +13.0%
Reported Mar 15, 2022 Mar 15, 2022 Mar 15, 2022 Mar 7, 2023 Mar 5, 2024 Mar 4, 2025 Mar 3, 2026

Operating KPIs — quarters

KPI Jun 24
Net revenue retention (%) 114.0%
Reported Aug 6, 2024

Operating KPIs — years

KPI Dec 2021 Dec 2023 Dec 2024 Dec 2025
Net revenue retention (%) 142.0% 130.0% 104.0% 115.0%
Reported Mar 15, 2022 Mar 4, 2025 Mar 4, 2025 Mar 3, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

SOPHiA GENETICS Reports Third Quarter 2026 Results Bull 4 Bear 0 Results

BOSTON, United States and ROLLE, Switzerland, November 3, 2026 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter ended September 30, 2026.

Third Quarter 2026 Financial Highlights

•Revenue was $24.3 million, up 25% year-over-year on a reported basis

•Gross margin was 65.7% on a reported basis and 72.8% on an adjusted basis, compared to 66.3% reported and 73.1% adjusted in the prior year period

•Net loss was $20.3 million, up 1% year-over-year; Adjusted EBITDA loss was $6.1 million, improving 31% year-over-year

•The company now expects full-year 2026 revenue to be at the upper end of its previously issued guidance range of $94 million to $96 million, reflecting strong business performance partially offset by the impact of foreign exchange rate movements at the end of the third quarter, which, if sustained would be a headwind to fourth-quarter revenue.

“Record analysis volume, strong performance in the U.S. market, and accelerating BioPharma momentum resulted in another excellent quarter as revenue grew 25% year-over-year,” said Ross Muken, Chief Executive Officer of SOPHiA GENETICS.

Press Release
Published on 20/10/26

BOSTON, United States and ROLLE, Switzerland, October 20, 2026 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the third quarter 2026 before U.S. markets open on Tuesday, November 3, 2026. On that day, SOPHiA GENETICS will host a conference call to discuss its […]

Home breadcrumb-arrow SOPHiA GENETICS to Announce Financial Results for Third Quarter 2026 on November 3, 2026

BOSTON, United States and ROLLE, Switzerland, October 20, 2026 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the third quarter 2026 before U.S. markets open on Tuesday, November 3, 2026. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET.

The call will be webcast live on the SOPHiA GENETICS Investor Relations Website . Additionally, a replay will be available on the website after its completion.

About SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) is an AI-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of SOPHiA DDM™, an AI platform that analyzes complex genomic and multimodal data to generate real-time, real-world insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn .

Investor Contact
Kellen Sanger
[email protected]

Media Contact
Sarah Mack
[email protected]

Sign Up To Our Newsletter

Enter your email address to join our mailing list and receive the latest news and updates from SOPHiA GENETICS. You can unsubscribe by using the link integrated with the communication at any time. By clicking to “sign up”, you agree that SOPHiA GENETICS will process your data in accordance with its Privacy Policy .

Email(Required)

Sign Up

Recent Press Releases

SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology   Read More

SOPHiA GENETICS Reports Second Quarter 2026 Results Read More

SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies Read More



For Providers


For BioPharma


For Patients

Democratizing data-driven medicine, together

Contact Us

Menu

close

Menu

close

Menu

close

© 2021 - 2024 SOPHiA GENETICS. All rights reserved.

Index égalité HF en France

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.

SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

Code Snippet ma-customfonts 3.4.2 closearrow-circle-o-downellipsis-v

Notifications

Close menu

Company News
Published on 08/10/26

BOSTON and SALT LAKE CITY - October 8, 2026 – SOPHiA GENETICS (NASDAQ: SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated […]

Home breadcrumb-arrow SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology 

BOSTON and SALT LAKE CITY - October 8, 2026 – SOPHiA GENETICS (NASDAQ: SOPH) and Myriad Genetics, Inc. , (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients. The collaboration aims to advance PrGIS in clinical trials and expand access to precision oncology medicines through potential companion diagnostic solutions. 

Myriad developed PrGIS to support HRD as an actionable biomarker in prostate cancer, where HRD is emerging as an important prognostic and predictive biomarker. The proprietary MyChoice® CDx test which is currently available as a companion diagnostic in ovarian cancer, will produce the PrGIS score and is being advanced for prostate cancer as a new indication. 

“This collaboration showcases Myriad’s biopharma capabilities to support development of precision oncology treatments,” said Lou Welebob, Senior Vice President, Companion Diagnostics, Myriad Genetics. “PrGIS is designed to provide biopharma partners with a platform that may support patient stratification in clinical trials and help accelerate companion diagnostic development for precision oncology therapies.” 

As part of the collaboration, SOPHiA GENETICS is developing its solid tumor application for Extended Homologous Recombination Solution into a decentralized companion diagnostic solution. The solution will incorporate Myriad’s PrGIS technology and aim to expand patient access to PrGIS in global markets. SOPHiA GENETICS’ technology-agnostic, cloud-based platform offers local laboratory testing across a global network of more than 1,000 connected institutions in over 75 countries. 

“Precision medicine has a geographic problem because breakthrough therapies developed in major markets often remain inaccessible to patients in the rest of the world,” said Jess Lambe, VP & Managing Director of BioPharma Business Development, SOPHiA GENETICS. “By pairing Myriad’s world-class biomarker innovation with SOPHiA GENETICS’ global network, we are working toward a solution for this. Together, we’re building a new model for companion diagnostic deployment that could help innovative therapies reach the right patients locally, expanding access to care where it matters the most.” 

Upcoming ESMO data to highlight PrGIS as a novel biomarker in prostate cancer 

Myriad also plans to present PrGIS research, co-authored with AstraZeneca, at the upcoming European Society for Medical Oncology (ESMO) Congress 2026. The research is expected to further characterize the biomarker and support its validation. Full data will be available following the ESMO embargo period. 

About SOPHiA GENETICS 

SOPHiA GENETICS (Nasdaq: SOPH) is an AI-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of SOPHiA DDMTM, an AI platform that analyzes complex genomic and multimodal data to generate real-time, real-world insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn . 

About Myriad Genetics  
Myriad Genetics is a leading molecular diagnostic and precision medicine company committed to advancing health and well-being for all. Myriad Genetics develops and commercializes molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs. For more information, visit www.myriad.com . 

SOPHiA GENETICS Safe Harbor Statement  

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the Company's plans to deploy PrGIS technology, the development of decentralized companion diagnostic solutions, the Company's global commercialization capabilities, and the expected benefits and reach of this collaboration. These "forward-looking statements" are management's expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such risks and uncertainties include those described in the Company's Annual Report on Form 20-F filed on March 3, 2026, as well as any updates to those risk factors filed from time to time in the Company's Reports on Form 6-K or other filings with the U.S. Securities and Exchange Commission. SOPHiA GENETICS is not under any obligation, and expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.  

Investor Contacts 

Kellen Sanger 
[email protected]  

Matt Scalo  
(801) 584-3532  
[email protected]   

Media Contacts 
Sarah Mack 
[email protected]  

Andria Rosell 
(385) 202-3510  
[email protected]   

Recent Company News

SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies Read More

SOPHiA GENETICS Signs Strategic Collaboration MOU with Leading Global Cancer Center   Read More

SOPHiA GENETICS and ARC Regulatory Collaborate to Support EU Clinical Trial Assay Development Read More



For Providers


For BioPharma


For Patients

Democratizing data-driven medicine, together

Contact Us

Menu

close

Menu

close

Menu

close

© 2021 - 2024 SOPHiA GENETICS. All rights reserved.

Index égalité HF en France

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.

SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

Code Snippet ma-customfonts 3.4.2 closearrow-circle-o-downellipsis-v

Close menu

Prompts

SOPHiA GENETICS SA (ticker SOPH), listed in United States.

ETFs Holding SOPHiA GENETICS SA

ETF Weight in ETF Shares Market value As of
MEDI 0.40% 23,315 $ 183.256K Nov 12, 2026